VRX Share Price

Open 12.67 Change Price %
High 12.84 1 Day 0.09 0.71
Low 12.42 1 Week 1.31 11.44
Close 12.76 1 Month -1.58 -11.02
Volume 977871 1 Year -31.48 -71.16
52 Week High 48.76
52 Week Low 11.20
VRX Important Levels
Resistance 2 13.15
Resistance 1 12.99
Pivot 12.67
Support 1 12.53
Support 2 12.37
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
RY 93.66 -1.90%
RY 93.66 -1.90%
HCG 8.02 33.89%
HCG 8.02 33.89%
HCG 8.02 33.89%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
CAM 12.19 96.61%
CAM 12.19 96.61%
CAM 12.19 96.61%
CAM 12.19 96.61%
CAM 12.19 96.61%
CAM 12.19 96.61%
More..
TSE Canada Top Losers Stocks
LRT-UN 0.03 -25.00%
GBV 0.46 -24.59%
HBP 0.76 -18.28%
HBP 0.76 -18.28%
AVP 0.06 -14.29%
AVP 0.06 -14.29%
AVP 0.06 -14.29%
AVP 0.06 -14.29%
CTU-A 0.19 -9.52%
GGA 0.10 -9.09%
More..

Valeant Pharmaceuticals (TSE: VRX)

VRX Technical Analysis 5
As on 27th Apr 2017 VRX Share Price closed @ 12.76 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 25.21 & Strong Sell for SHORT-TERM with Stoploss of 15.85 we also expect STOCK to react on Following IMPORTANT LEVELS.
VRX Target for April
1st Target up-side 17.73
2nd Target up-side 19.86
3rd Target up-side 21.99
1st Target down-side 11.65
2nd Target down-side 9.52
3rd Target down-side 7.39
VRX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.valeant.com
VRX Address
VRX
2150 St. Elz
Laval, QC H7L 4A8
Canada
Phone: 514-744-6792
Fax: 514-744-6272
VRX Latest News
Valeant Pharmaceuticals Intl Inc (VRX) Stock Still Looks Toxic   Investorplace.com   - 27th Apr 17
It's Time To Talk About Valeant   Seeking Alpha   - 27th Apr 17
Valeant Pharmaceuticals Intl Inc's (VRX) Bausch + Lomb Announces 510(k ...   Smarter Analyst   - 26th Apr 17
Valeant Can Beat Guidance   Seeking Alpha   - 26th Apr 17
Valeant: The Math Doesn't Add Up   Seeking Alpha   - 25th Apr 17
Valeant Is Unfairly Undervalued II   Seeking Alpha   - 24th Apr 17
Odds Shaky on Valeant Pharmaceuticals Intl Inc (VRX), Hint of Promise for ...   Smarter Analyst   - 22nd Apr 17
Valeant Pharmaceuticals Intl Inc (VRX) Is a Dead Drugmaker Walking   Investorplace.com   - 21st Apr 17
3 Stocks to Watch on Friday: Visa Inc (V), Valeant Pharmaceuticals Intl Inc ...   Investorplace.com   - 21st Apr 17
Valeant prices psoriasis treatment at $3500 per month   Reuters   - 21st Apr 17
Interactive Technical Analysis Chart Valeant Pharmaceuticals ( VRX TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Valeant Pharmaceuticals
VRX Business Profile
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Its pharmaceutical products include Solodyn, an oral antibiotic that treats red and pus-filled pimples, as well as Ziana, Acanya, and Atralin; Wellbutrin XL, a formulation used for the treatment of major depressive disorder in adults; Xenazine for the treatment of chorea; Zovirax Cream for herpes labialis; Zovirax ointment for initial genital herpes; The Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; and Prolensa, a non-steroidal anti-inflammatory ophthalmic solution. The company also provides OTC products, such as PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus, a sterile that is used to lubricate and rewet soft contact lenses; Ocuvite, a lutein eye vitamin and mineral supplement; Artelac, an eye drops to treat dry eyes; and CeraVe products for skin. In addition, it offers device products, including SofLens daily disposable contact lenses; Restylane, an injectable implant dermal fillers; PureVision, a contact lens; Dysport, an injection neurotoxin; ophthalmic surgical products, such as Akreos and Crystalens; surgical equipment comprising the VICTUS femtosecond laser and the Stellaris PC, a vitreoretinal and cataract surgery system; and medical device systems for aesthetic applications. Further, it provides generic products comprising Retin-A Micro, a tretinoin gel; tobramycin and dexamethasone ophthalmic suspensions for steroid responsive inflammatory ocular conditions; and latanoprost to treat glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.